Our data lead to the hypothesis that, in addition, modulation of innate immune responses via NR-regulated expression of hBD-1 could be in parts responsible for the positive effects of fibrates and FXR-agonists in cholestatic liver diseases by enhancing the antibacterial defense and controlling bacterial infection in cholestatic liver tissue. This evidence concerns the gene DEFB1 and bacterial infectious disease.